ALTSTATION.IO

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$648.34

Change

+0.74%

Market Cap

$51.87B

Avg Volume

539.2K

Company Overview

IDEXX Laboratories, Inc. develops and sells diagnostic products and services for the veterinary industry, livestock, poultry, and water testing. Their offerings include in-clinic testing equipment, rapid assay kits, and reference laboratory services. Key customers are veterinarians, livestock producers, and water testing facilities in the U.S. and internationally. The company operates in three segments: Companion Animal Group, Water Quality Products, and Livestock, Poultry, and Dairy.

IDEXX is a market leader, especially in the companion animal diagnostics space, where they hold a significant share. Their edge stems from a broad product portfolio, strong brand reputation, and a robust distribution network. However, competition is heating up from companies like Zoetis and Neogen, which also target these markets. The need for rapid and accurate diagnostic tools in the veterinary and food safety sectors creates opportunities but also puts pressure on IDEXX to innovate continuously.

Currently, IDEXX is in a growth phase. The company reported a 12% increase in revenue year-over-year in Q3 2023, driven by strong demand for its Companion Animal Group products. Recent strategic initiatives, such as enhancements in their VetConnect PLUS cloud-based platform, position them well for future growth. Their focus on expanding international markets and advancing diagnostic technology indicates they are actively looking to strengthen their market position.

Key Financials

Market Cap

$51.87B

Revenue

$4.30B

EBITDA

$1.50B

Gross Margin

61.8%

Profit Margin

24.6%

Revenue Growth

14.3%

Total Cash

$180.07M

Total Debt

$847.84M

Free Cash Flow

$628.05M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

49.64

Forward P/E

39.58

Beta

1.66

52-Week High

$769.98

52-Week Low

$356.14

EPS

$13.06

50-Day Avg

$699.81

200-Day Avg

$615.10

Price/Book

32.27

Technical Analysis

IDEXX Laboratories, Inc. (IDXX) has demonstrated a strong upward trend over the past 52 weeks, culminating in a current price of $648.34, a significant gain of 38.7%. Key support is located around $644.61, which appears to have held as the price approached that level recently. Resistance is seen near the $700 mark, where the stock has struggled to maintain momentum in the past. In terms of price patterns, there have been notable fluctuations, with peaks in August and early January indicating increased volatility. However, the recent momentum has shown a slight pullback from recent highs, suggesting a potential consolidation phase. The current price sits well above the 52-week low of approximately $400, indicating bullish sentiment, but the recent hesitance near resistance levels highlights a need for confirmation of continued strength.

Recent News and Developments

Here’s a summary of the latest news and developments for IDEXX Laboratories, Inc

(IDXX) stock in the past week, covering February 1, 2026, to February 7, 2026:

Market Update

### IDEXX Beats Q4 2025 Earnings and Revenue Estimates, Provides 2026 Guidance

Market Update

IDEXX Laboratories (NASDAQ: IDXX) announced its fourth-quarter and full-year 2025 results on February 2, 2026, reporting diluted earnings per share (EPS) of $3.08, surpassing the analyst consensus estimate of $2.93. Quarterly revenue also exceeded expectations, coming in at $1.09 billion against a consensus estimate of $1.07 billion, representing a 14% year-over-year increase. The company attribut

Market Sentiment and Analyst Recommendations

Bull Case

IDEXX just beat Q4 estimates and raised 2026 guidance, which is the opposite of what most beaten-down stocks do. Revenue growth at 14.3% is solid for a $51.87B company, and the Companion Animal Group is firing on all cylinders with record placements of 1,900+ inVue Dx systems. The 2026 guidance of 7.6% to 9.6% reported growth and 7.0% to 9.0% organic growth is respectable given the macro headwinds, and CAG Diagnostics recurring revenue is expected to grow 8% to 10% organically. Thirteen analysts recommend buy, with a consensus target of $752.15, suggesting 16% upside from current levels. The stock has already priced in some pain from the CEO transition and pet visit declines, making the risk-reward favorable for patient investors. IDEXX dominates the veterinary diagnostics space with recurring revenue streams that are relatively insulated from economic cycles.

Bear Case

The P/E of 49.64 is punchy for a company guiding to mid-single-digit organic growth. IDEXX explicitly flagged that declining pet visits will drag 2026 results by 200 basis points, which is a meaningful headwind and signals consumer stress in the pet care category. The stock dropped 4% immediately after earnings despite beating estimates, and the CEO departure in May adds execution risk during a critical transition period. Total debt sits at $847.84M against only $180.07M in cash, giving the company limited financial flexibility if growth slows further or macro conditions deteriorate. The analyst price target range is wide, from $470 to $823, indicating genuine disagreement about fair value. Resistance at $700 has proven sticky, and the recent pullback suggests momentum may be fading after the 38.7% year-to-date run.

What to Watch

Monitor the new CEO’s first earnings call in May and what strategic direction they signal for the business. Track pet visit volume trends quarter-to-quarter in 2026, since the company admitted this is a 200 basis point drag and it’s the clearest indicator of consumer health. Watch for recurring revenue growth rates in CAG Diagnostics, which should hold at 8% to 10% organically if the guidance is credible. The $700 resistance level is critical; a sustained break above it signals institutional conviction, while a failure to hold $644 support would confirm weakness. Monitor analyst revisions closely after Q1 2026 earnings in April, particularly whether the 200 basis point pet visit headwind materializes as expected. If IDEXX can deliver organic growth in the 8% to 9% range while maintaining margins, the valuation becomes more defensible and could support multiple expansion.

Analyst Consensus

BUY

Based on 13 analyst opinions

Low Target

$470.00

Mean Target

$752.15

High Target

$823.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

11,000

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$13.06

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is IDXX a good stock to buy?

Analysts recommend buying IDXX with a target price of $752.15, suggesting upside potential from the current price of $648.34. The growth prospects in the healthcare diagnostics sector bolster this recommendation.

What is IDXX’s price target?

The current analyst consensus gives IDXX a target price of $752.15. This represents a potential increase of about 15.95% from the current trading price.

Does IDXX pay a dividend?

IDXX does not pay a dividend. With a focus on growth and reinvestment, investors looking for income might need to consider other options.

What is the P/E ratio of IDXX?

IDXX has a P/E ratio of 49.64 and a forward P/E of 39.58. These figures indicate that the stock is currently priced for significant growth, reflecting high investor expectations.

What is IDXX’s market cap?

IDXX Laboratories has a market cap of $51.87 billion. This positions the company as a significant player in the diagnostics and research sector within healthcare.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.